Brought to you by Hardman & Co and London South East, we would be delighted if you would join us for our Life Sciences Investor Briefing.
Date / Time: Wednesday 11th September 2019 | Doors 5:45 pm | Live 6.15 pm
Location: Brewers Hall, Aldermanbury Square (Off London Wall), London , EC2V 7HR
The Investor Briefing connects investors with companies looking for capital. It is an exclusive event for individuals seeking investment opportunities; places are limited.
Attendees will have the opportunity to hear from Hardman & Co analyst Martin Hall, and the following companies:
Destiny Pharma plans to generate income and shareholder value by the clinical development and commercial exploitation of its proprietary, highly innovative anti-bacterial drug platform. The XF drug platform is being developed to prevent and treat existing and emerging superbug infections within and outside of hospitals.
The main market for the lead asset XF-73, which is currently in Phase 2 clinical studies, is the prevention of post-surgical infections such as MRSA. The commercial focus is initially in the USA but the need for a new treatment is global and Destiny Pharma has the ability to enter into licensing agreements and collaborations for other territories in due course. For example, the agreement signed in 2017 with China Medical Systems is a broad collaboration to develop the company’s assets in the China/Asia market.
The Board believes that the increasing governmental pressure and financial incentives that are being implemented now and possibly in the future by leading institutions such as the WHO, UN, FDA and G7/G20 will increase further the options available for profitable commercialisation and the generation of shareholder value.
Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients’ unmet medical needs.
The Group has a marketed product, Feraccru®/Accrufer®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s.
Feraccru®/Accrufer® is approved by the FDA, EMA and Swiss Medic for the treatment of iron deficiency in adults and is commercialised in the European Union by Norgine BV, with a US commercialisation partner currently being selected.
Open Orphan plc is a European-focussed, rare and orphan drug consulting services platform. The Company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health Data Platform to partner with Patient Advocacy Groups.
The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.
For over 20 years, Hardman & Co has built a reputation for research of the highest quality, provided by a team of highly skilled and qualified industry professionals. The Life Sciences team, led by Dr Martin Hall, has a reputation for opinionated research that is distributed globally in the fields of pharmaceuticals, biotechnology, medical technology and healthcare.
Our strengths are industry knowledge, quality of product, and excellent distribution. Our reports tend to be more in-depth and more educational, but still getting messages across to all pools of capital, so they sit comfortably alongside, and are complementary to those of the company’s own broker.
Nigel Cassidy, our regular event presenter, is a highly experienced financial host, writer and broadcaster – perhaps best known for his years presenting the business news on BBC Radio 4’s iconic Today programme, and for the time he spent on the road as a roving TV business correspondent for BBC World News. He also hosted Share Radio’s breakfast show.